By Admin at 25 Jan 2017
Women with advanced ovarian cancer may have a new option for treatment. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Rubraca (rucaparib), a poly ADP-ribose polymerase (PARP) inhibitor.
By Admin at 13 Jul 2016
A new study showed that incorporating immunotherapy into ovarian cancer treatment might combat chemotherapy resistance and improve survival rates.
By Admin at 5 Jan 2016
Unfortunately, only about 20 percent of ovarian cancers are currently detected in the early stages. A new blood test may change that, however, according to a study by researchers at the Georgia Institute of Technology.
By Admin at 9 Dec 2015
One of the main hurdles to increasing outcomes among ovarian cancer patients is resistance to chemotherapy. It’s estimated that 75 percent of women with advanced ovarian cancer initially respond to chemotherapy treatment, but the majority will relapse within two years.
By Admin at 14 Oct 2015
Preventive surgery is a drastic cancer solution, however, which carries a risk of both physical and psychological consequences. In the case of ovarian cancer, it’s possible the surgery may also not entirely prevent the cancer from forming. Alternatives to lower cancer risk in women with BRCA 1 and BRCA2 mutations are greatly needed, and two new studies offer potential solutions.
58
Current Gateway-funded clinical trials
150+
Clinical trials funded at leading institutions worldwide
$16.56
Funds one patient for one day at a Gateway-funded clinical trial